The DEA Just Scheduled the Thing People Used to Get Off Opioids. It Built Them Nothing to Replace It.

He was forty-three, three years out from thoracic outlet surgery, and by the time physicians wrote him up as a case report in a peer-reviewed journal, he had a system: hydromorphone for the pain, ten milligrams a day, injected. And kratom, ordered online, for the days the hydromorphone ran out — because a gap in an opioid supply doesn’t pause the withdrawal clock. He told his doctors kratom did something hydromorphone didn’t: took the pain down without the fog. He also told them, and his wife confirmed it, that he spent fifteen thousand dollars a year on it. The withdrawal coming off kratom ran longer than coming off the hydromorphone, but softer — an ache that stretched out instead of one that slammed.

That case sat in the medical literature as a curiosity: a patient who built his own bridge therapy out of a tree leaf because nobody built him one. On July 1, 2026, the DEA announced it is closing that bridge. Not for whole-leaf kratom — the agency is being careful this time — but for 7-hydroxymitragynine, or 7-OH, the concentrated compound inside kratom that does most of the opioid-like work, sold at gas stations and vape shops as tablets and gummies at doses raw leaf can’t touch.

The DEA is not banning a drug of abuse. It is banning the only bridge some people had, and it still hasn’t built the thing on the other side.

The Federal Register notice, published July 6, sets a threshold: any botanical kratom material above 0.050% 7-OH by dry weight, or any synthetic product above 0.050% or 1.00 milligram, moves into Schedule I — the same legal category as heroin and LSD. Two related compounds, mitragynine pseudoindoxyl and a pair of lab-derivative analogs called MGM-15 and MGM-16, go with it. The order can’t take effect before August 5. After that, thirty days and a Federal Register signature is most of what stands between today’s legal gas-station purchase and a federal drug charge.

If you’ve used 7-OH to get through withdrawal, or to keep working through pain nobody would prescribe you real medication for, you already know none of this is abstract. You know what the tablets cost, what the crash feels like when you run out, and that “concentrated kratom extract” doesn’t sound like heroin until you’re the one facing what the law now calls it.

The DEA already tried this once. It didn’t go the way anyone expected.

This is not the DEA’s first swing at kratom, and the agency knows it. On August 31, 2016, it filed a near-identical notice — except that one covered all kratom, mitragynine and 7-OH together, not just the concentrated derivative. The public reaction was not the muted regulatory-comment-period trickle DEA notices usually get. It was a mobilization. Protesters gathered outside DEA headquarters. A White House petition to reverse the ban collected more than 142,000 signatures. More than fifty members of Congress, from both parties, wrote to demand the agency slow down. DEA spokesman Russ Baer told reporters the agency had fielded over 2,000 phone calls, the overwhelming majority opposed. On October 12, 2016 — six weeks after announcing the ban — the DEA formally withdrew it and opened a public comment period instead. CNN covered the reversal as a rare instance of a federal scheduling decision undone by public pressure before it ever took effect.

We have watched a federal agency try to make a broad-strokes call about a substance millions of people use for pain and withdrawal before, and watch that call collapse under the weight of the people it would have criminalized. The lesson the DEA took from 2016 was narrow and legally precise: leave the leaf alone, target the concentrate. It was not the lesson that mattered more — that scheduling a substance without funding a replacement for what it was doing just moves the crisis somewhere less visible.

The lesson the DEA took from 2016 was narrow and legally precise: leave the leaf alone, target the concentrate.

Why the “concentrated, not botanical” distinction matters — and why it isn’t the whole story

Here’s the plain-language version of what the DEA is actually doing, because the difference between “kratom” and “7-OH” gets flattened in most headlines. Kratom leaf naturally contains a range of alkaloids, mostly mitragynine, in modest concentrations. 7-OH is a minor, secondary alkaloid in raw leaf — present in trace amounts — that manufacturers can isolate and concentrate into products with far higher potency than anything a person chewing leaf or drinking tea could reach. Virginia Commonwealth University’s Dr. John Downs, who directs the state’s poison center, has described 7-OH as five to fifteen times more potent than morphine at the concentrations now sold as tablets and gummies. That is not a botanical supplement. That is a manufactured opioid-receptor agonist wearing a kratom label, sold next to energy drinks with no prescription, no dosing guidance, and — until August — no scheduling.

The American Kratom Association, the industry’s most visible advocacy group, applauded the DEA’s move — a telling detail, since AKA fought the 2016 ban with everything it had. AKA has spent the years since 2016 trying to draw a bright line between “our product” (whole-leaf kratom, which the group insists is safer and used mostly for pain and mood) and “their product” (concentrated 7-OH extracts, which AKA has lobbied state legislatures to restrict on its own). The industry and the DEA agree on where the line should be drawn. What neither of them has answered is what happens to the people already on the wrong side of it.

The part the DEA’s press release doesn’t mention

Read the case reports and the clinical accounts and a pattern surfaces that has nothing to do with getting high. A Psychology Today account describes a woman in her twenties who started on 7-OH gummies bought at a vape shop and ended up in detox with withdrawal her clinicians described as identical to opioid withdrawal in kind and comparable to fentanyl in intensity — profuse sweating, vomiting, cravings she couldn’t out-wait. She lost her job before she found treatment. A separate account in the same piece describes a patient spending three hundred dollars a day on 7-OH doses, waking at 2 a.m. in withdrawal despite dosing at 8 p.m. the night before, cycling through aches, nausea, and — worth saying plainly, because minimizing it doesn’t help anyone — suicidal thoughts as the drug wore off. Psychologists have a name for why a gas-station gummy can produce fentanyl-grade withdrawal: 7-OH binds the mu-opioid receptor with an efficacy that rivals full opioid agonists, even though the label never says “opioid.” The proof isn’t the pharmacology paper. The proof is the person in the detox bed who didn’t know what she’d gotten dependent on until it was already gone.

None of that argues against regulating 7-OH. It argues against regulating it as though the regulation itself is the intervention. A Schedule I order removes a product from shelves. It does not treat a single person’s withdrawal, fund a single new bed, or answer the question a person physically dependent on 7-OH will be asking on August 6: what do I do now that this is illegal and I’m still dependent on it.

What actually happens on the ground when the order takes effect

Here is the gate that matters, and it’s the one most coverage of this story skips: temporary Schedule I status is not permanent, and it does not, on its own, create a single new treatment pathway. It criminalizes possession and distribution above the threshold. It does not fund detox. It does not train emergency physicians on 7-OH-specific withdrawal management, which — per the case accounts above — clinicians are already describing as harder to predict than standard opioid withdrawal because 7-OH’s pharmacokinetics and receptor profile don’t map cleanly onto methadone or buprenorphine dosing charts built for full-agonist opioids. The companion HHS request for information, filed alongside the DEA notice, is explicitly seeking clinical data before any permanent scheduling decision — which means the agency itself is acknowledging how thin the evidence base still is, three weeks before enforcement starts.

For a provider or case manager reading this: if your intake process asks about opioid use, it is very likely not currently asking about 7-OH specifically — and after August 5, patients have every incentive to describe a felony-adjacent dependence as “just kratom” unless you ask the more precise question. Build the follow-up into your next team meeting: does your screening protocol distinguish whole-leaf kratom use from concentrated 7-OH products, and does your withdrawal-management pathway account for a receptor profile that doesn’t behave like standard full-agonist opioids?

What’s still yours, regardless of what changes on August 5

If you are dependent on 7-OH and reading this before the order takes effect, or after, the scheduling change does not touch the things that keep people alive during withdrawal from anything opioid-like. Naloxone still reverses an overdose whether the opioid involved is fentanyl, a nitazene, or a 7-OH product strong enough to depress your breathing — carry it, and know that federal funding for distributing it, unlike funding for 7-OH-specific treatment, was just expanded, not cut. Medical detox and buprenorphine-based treatment exist independent of what a substance is scheduled as; you do not need to wait for 7-OH-specific protocols to walk into an emergency department in withdrawal and ask for help. None of that is contingent on Congress, the DEA, or the AKA resolving their argument about where the regulatory line belongs.

None of that is contingent on Congress, the DEA, or the AKA resolving their argument about where the regulatory line belongs.

The bridge, still half-built

Nine years after the DEA backed down from banning kratom outright, it has landed on a narrower, more legally defensible version of the same idea — and it arrives having learned exactly one lesson from 2016: which substance to leave alone so the backlash stays small. It has not learned the other lesson, the one that was always the real one. A scheduling order is not a treatment plan. It is a door closing on one side of a bridge that people like the forty-three-year-old in that case report built for themselves because the health system didn’t build one for them first. On August 5, that bridge gets a felony sign posted on it. The people already standing on it don’t disappear. They just stop having anywhere the DEA’s press release accounts for.